(Q38033125)

27 August 2017

Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review (English)

1 reference

27 August 2017

1 reference

Li Guo

1

1 reference

27 August 2017

Xiao-xiang Chen

2

1 reference

27 August 2017

Yue-ying Gu

3

1 reference

27 August 2017

He-jian Zou

4

1 reference

27 August 2017

Shuang Ye

5

1 reference

27 August 2017

9 August 2012

1 reference

27 August 2017

Clinical Rheumatology

1 reference

27 August 2017

31

1 reference

27 August 2017

9

1 reference

27 August 2017

1395-1400

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

27 August 2017

1 reference

Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

Imatinib for the treatment of refractory, diffuse systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

Is imatinib mesylate a promising drug in systemic sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

Molecular framework for response to imatinib mesylate in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

Imatinib mesylate in the treatment of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2032-2

Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases

21 January 2018

1 reference

12 December 2020

Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma

1 reference

12 December 2020

Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis

1 reference

12 December 2020

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

1 reference

12 December 2020

Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

1 reference

12 December 2020

10.1007/S10067-012-2032-2

Identifiers

DOI

1 reference

27 August 2017

1 reference